Menu
Not yet recruiting NCT07700979

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Phase III Interventional Gastric / Gastroesophageal Junction Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cadonilimab, CAPOX regimen, Nivolumab, Placebo.
Who it may be relevant to
Registry conditions: Gastric / Gastroesophageal Junction Adenocarcinoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, China, Germany, Poland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized, Double-blind, Multi-regional Phase 3 Study of Cadonilimab Combined With Chemotherapy Versus Chemotherapy in Combination With or Without Nivolumab for the First-line Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Overview

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.

Interventions

  • Drug Cadonilimab
    Anti-PD-1/ CTLA-4 tetrameric bispecific antibody
  • Drug CAPOX regimen
    A combination treatment contains oxaliplatin and capecitabine
  • Drug Nivolumab
    Anti-PD-1 monoclonal antibody
  • Drug Placebo
    Placebo

Primary outcome measures

  • Overall survival (OS) [Time frame: Approximately up to 14months]
Secondary outcome measures (5)
  • Progression-free survival(PFS) [Time frame: Approximately up to 8 months]
  • Objective response rate (ORR) [Time frame: Approximately up to 8 months]
  • Disease control rate (DCR) [Time frame: Approximately up to 8 months]
  • Duration of response (DoR) [Time frame: Approximately up to 8 months]
  • Safety assessment [Time frame: Approximately up to 18 months]

Eligibility criteria

Inclusion criteria

  • Able to provide written informed consent and can understand and comply with the requirements of the study.
  • Histopathologically-confirmed diagnosis of locally advanced unresectable or metastatic G/GEJ adenocarcinoma.
  • No prior systemic therapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma. NOTE: For participants who have received prior neoadjuvant/adjuvant therapy for curative intent, the time between disease progression and last treatment should be at least 6 months.
  • ECOG PS of 0 or 1 within 3 days prior to randomization.
  • Age ≥ 18 years at the time of voluntarily signing informed consent.
  • Evaluable PD-L1 expression results.
  • Participants must have at least one measurable lesion per RECIST v1.1 as assessed by investigator assessment. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Adequate organ function as indicated by the following laboratory values. Specimens must be collected within 7 days prior to the first dose of study treatment.
  • Life expectancy ≥3 months.
  • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective contraception during treatment, and for at least 150 days after the last dose of cadonilimab/nivolumab, 270 days after the last dose of oxaliplatin, and 180 days after the last dose of capecitabine.
  • Non-sterile males must agree to use effective contraception during treatment and for at least 120 days following the last dose of cadonilimab/nivolumab/capecitabine and 180 days after the last dose of oxaliplatin.

Exclusion criteria

  • Histopathologically confirmed other pathological types, such as squamous cell carcinoma, sarcoma or undifferentiated carcinoma.
  • Known HER2 positive. Be HER2-positive defined as either IHC 3+ or IHC 2+ in combination with ISH+ (or FISH).
  • Participants with active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.
  • Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1 time/month).
  • Clinically significant bleeding symptoms within 28 days before the first dose or a definite tendency to bleed.
  • Have a history of ≥ Grade 2 gastrointestinal perforation and/or fistulae (including prior gastric fistula operation) within 6 months prior to randomization.
  • Participants who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 13 centers
  • Mayo Clinic — Phoenix
  • UCLA Health — Los Angeles
  • Rocky Mountain Cancer Centers — Denver
  • Yale School of Medicine — New Haven
  • Dana Farber Cancer Institute — Boston
  • Henry Ford Health — Detroit
  • Mount Sinai — New York
  • Memorial Sloan Kettering Cancer Center — New York
  • … and 5 more centers
China · 5 centers
  • Beijing Friendship Hospital, Capital Medical University — Beijing
  • Peking University Cancer Hospital, Gastrointestinal Cancer Center I — Beijing
  • Peking University Cancer Hospital, Gastrointestinal Oncology — Beijing
  • Guangdong Provincial People's Hospital — Guangzhou
  • Zhongshan Hospital Fudan University — Shanghai
Germany · 4 centers
  • Universitaetsklinikum Essen — Essen
  • University Cancer Center Frankfurt — Frankfurt
  • Universitätsmedizin der Johannes Gutenberg-Universität — Mainz
  • Univerity Marburg — Marburg
Poland · 3 centers
  • Pratia MCM Kraków — Krakow
  • Pratia Poznań — Poznan
  • Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w W — Warsaw

Identifiers

NCT: NCT07700979 · AK104-311

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗